Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ME 344

Drug Profile

ME 344

Alternative Names: ME-344; NV-344

Latest Information Update: 07 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novogen
  • Developer MEI Pharma; Sarah Cannon Research Institute; Spanish National Cancer Research Centre; Tennessee Oncology
  • Class Antineoplastics; Isoflavones; Small molecules
  • Mechanism of Action Mitochondrial oxidative phosphorylation inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer
  • Preclinical Acute myeloid leukaemia
  • No development reported HER2 negative breast cancer
  • Discontinued Cervical cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 08 May 2023 Phase-I clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT05824559)
  • 30 Apr 2023 MEI Pharma plans a phase Ib trial for Colorectal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) (IV) in April 2023 (NCT05824559)
  • 01 Dec 2022 US FDA approves IND application for ME 344 plus Avastin®(bevacizumab) in Colorectal cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top